This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Boneschi, F. M. Articles by Filippi, M. Search for Related Content PubMed PubMed Citation Articles by Boneschi, F. M. Articles by Filippi, M. Social Bookmarking                         What's this?

The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials

Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy

Marco Rovaris

Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy, Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy

Giancarlo Comi

Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy

Massimo Filippi

Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy, Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy, filippi.massimo{at}hsr.it

Magnetic resonance imaging (MRI) is an important paraclinical tool for the diagnosis of multiple sclerosis (MS) and for monitoring its disease course. The efficacy of most of the available MS disease-modifying treatments has been tested in clinical trials where MRI-derived quantities served as primary or secondary outcome measures. However, conventional MRI measures (i.e., the number and volume of contrast-enhancing, the volumes of T2-hyperintense and T1-hypointense lesions and the assessment of brain volume changes) are limited in terms of pathological specificity and, as a consequence, are modestly correlated with clinical measures of disease activity and have a modest prognostic value as predictors of MS evolution. In the present review, we discuss the main factors potentially responsible for the so-called ‘clinicaluMRI paradox’ and how modern quantitative MR-based techniques might contribute to, at least partially, overcome it. The lessons learned from MS trials suggest that future applications of MRI to assess MS evolution should rely upon the use of composite measures thought to reflect the various components of the disease, as well as on study protocols specifically designed on the individual trial characteristics.

Key Words: clinical trials • magnetic resonance imaging • multiple sclerosis

Multiple Sclerosis, Vol. 10, No. 4, 341-347 (2004)
DOI: 10.1191/1352458504ms1067rr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A Charil, D Caputo, R Cavarretta, M P Sormani, P Ferrante, and M Filippi Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study Multiple Sclerosis, September 1, 2006; 12(5): 662 - 665. [Abstract] [PDF]